Features - Bayer


Current filters:


Popular Filters

298 to 322 of 343 results

Outlook for VTE treatment and prophylaxis market


Driven primarily by the launches and strong uptake of oral anticoagulants, the combined markets for drugs…

BayerBristol-Myers SquibbCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

News briefs from breast cancer meeting


In further news from the the San Antonio Breast Cancer Symposium (SABCS) that took place in Texas, USA…


Mixed views on drospirenone OCs


The majority of members of the US Food and Drug Administration’s Reproductive Health Drugs Advisory…

BayerDrospirenone and EstradiolNorth AmericaPharmaceuticalRegulationReproductiveWomen's HealthYasminYaz

Phase III trial of Regeneron and Bayer’s Eylea initiated in China


USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) and German partner Bayer (BAY: DE) have initiated…


FDA approves Regeneron’s Eylea for wet age-related macular degeneration


Following unanimous advisory panel support for the drug, the US Food and Drug Administration has approved…

BayerBiotechnologyEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Bayer plans further capital spending of 1.8 billion euros in Asia


German pharma, crop and material sciences group Bayer (BAY: DE) this morning disclosed plans to further…

Asia-PacificBayerFinancialMarkets & MarketingPharmaceutical

Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif


US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) says that the Phase…


Bayer 3rd-qtr 2011 results show strong Pharma offsetting weakness in MatSci


German pharma, crop and materials sciences group Bayer AG (BAY: DE) posted a healthy set of third-quarter…


Bayer halts regorafenib trial for colorectal cancer on good Ph III results


USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Bayer signs MoU to establish pharmaceutical production in Russia


In a move that indicates it is going to join the ranks of other drug giants by making major investments…

BayerEuropeFinancialMarkets & MarketingPharmaceuticalResearch

Bayer celebrates 100 years in Japan, planning continued growth there despite difficult conditions


Germany’s pharma, and material and crop sciences group Bayer (BAY: DE) says it plans to expand its…


US FDA communicates concern about drospirenone-containing birth control pills


The US Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion,…

BayerDrospirenone and Ethinyl EstradiolNorth AmericaPharmaceuticalRegulationReproductiveYasminYaz

EMA advisory panel backs Bayer’s Xarelto for AF-related stroke prevention and DVT


There was more good news for Bayer HealthCare, the pharma unit of Germany’s Bayer AG (BAY: DE),…


Positive first Phase III trial of an alpha-pharmaceutical, Bayer’s Alpharadin


Until recently, options for patients with bone metastases from advanced prostate cancer have been very…


US FDA advisory panel backs approval of Bayer/J&J’s Xarelto for stroke prevention


There must have been a palpable sigh of relief last night across Leverkusen, the headquarters of Germany’s…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Disappointing FDA briefing papers on Bayer/J&J’s Xarelto


US Food and Drug Administration staffers posted a negative picture for German drug major Bayer (BAY:…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Changing the mood of Brazilian antidepressant market; fake Levitra


The Vice President of Brazil’s Superior Court of Justice (STJ), Minister Felix Fischer, has restored…

BayerGenericsLevitraLexaproLundbeckNeurologicalPharmaceuticalRegulationReproductiveSouth America

US FDA fast-tracks Bayer and Algeta’s prostate drug Alpharadin


Germany’s Bayer (BAY: DE) said this morning that its investigational compound Alpharadin (radium-223…

AlgetaAlpharadinBayerNorth AmericaOncologyPharmaceuticalRegulation

Bayer reprimanded for breaches of the ABPI Code by tweeting on Rx drugs


The UK Prescription Medicines Code of Practice Authority (PMCPA) has reprimanded Bayer Healthcare, a…

BayerEuropeLevitraMarkets & MarketingPharmaceuticalRegulationSativex

US FDA delays decision on Regeneron’s wet AMD drug Eylea


US biotech firm Regeneron Pharmaceuticals. (Nasdaq: REGN) says that it has received notification from…

BayerBiotechnologyEyleaNorth AmericaOphthalmicsRegeneronRegulation

Bayer makes moxifloxacin available to help WHO TB program in China


Bayer HealthCare, a unit of Germany’s Bayer AG (BAY: DE), has agreed to support the World Health…

Antibiotics and Infectious diseasesAsia-PacificBayerMarkets & MarketingMoxifloxacinPharmaceutical

298 to 322 of 343 results

Back to top